Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q96PZ2

UPID:
F111A_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q96PZ2; A8K5Y8; Q5RKS9; Q5XKM2; Q68DK9; Q6IPR7; Q9H5Y1

BACKGROUND:
The Serine protease FAM111A is crucial for DNA synthesis and S-phase entry, promoting genomic stability by facilitating PCNA loading on replication sites and protecting replication forks from stalling. Its ability to remove DPCs, including those involving trapped topoisomerase 1 and PARP1-DNA complexes, underscores its vital role in preserving the integrity of the genome during cell division.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in DNA repair and cell cycle progression, Serine protease FAM111A represents a promising target for developing treatments for conditions like Kenny-Caffey syndrome 2 and Gracile bone dysplasia. Exploring the therapeutic potential of targeting FAM111A could lead to innovative strategies to combat these and potentially other related genetic diseases, marking a significant step forward in personalized medicine.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.